UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Some Identities Involving the Cesàro Average of the Goldbach Numbers

Mathematical Notes, 2019-11, Vol.106 (5-6), p.688-702

Cantarini, M.

2019

Volltextzugriff (PDF)

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Annals of oncology, 2018-03, Vol.29 (3), p.687-693

2018

Volltextzugriff (PDF)

Recent advances in the natural history of hepatocellular carcinoma

Carcinogenesis (New York), 2008-07, Vol.29 (7), p.1299-1305

2008

Volltextzugriff (PDF)

Aspartyl‐asparagyl β hydroxylase over‐expression in human hepatoma is linked to activation of insulin‐like growth factor and notch signaling mechanisms

Hepatology (Baltimore, Md.), 2006-08, Vol.44 (2), p.446-457

2006

Volltextzugriff (PDF)

LBA2_PR Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S153

2016

Volltextzugriff (PDF)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

British journal of cancer, 2009-11, Vol.101 (10), p.1724-1730

2009

Volltextzugriff (PDF)

The effect of fluconazole on the pharmacokinetics of rosuvastatin

European journal of clinical pharmacology, 2002-11, Vol.58 (8), p.527-531

2002

Volltextzugriff (PDF)

134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S153-S154

2016

Volltextzugriff (PDF)

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

International journal of pharmaceutics, 2009-07, Vol.376 (1), p.7-12

2009

Volltextzugriff (PDF)

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S154

2016

Volltextzugriff (PDF)

Aspartyl-(asparaginyl)-β-hydroxylase regulates hepatocellular carcinoma invasiveness

Journal of hepatology, 2006-05, Vol.44 (5), p.971-983

2006

Volltextzugriff (PDF)

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

Drug metabolism and disposition, 2016-08, Vol.44 (8), p.1201-1212

2016

Volltextzugriff (PDF)

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

European journal of cancer (1990), 2015-09, Vol.51, p.S625-S626

2015

Volltextzugriff (PDF)

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)

Annals of oncology, 2014-09, Vol.25, p.iv152

2014

Volltextzugriff (PDF)

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

European journal of cancer (1990), 2015-09, Vol.51, p.S640-S640

2015

Volltextzugriff (PDF)

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Clinical cancer research, 2016-10, Vol.22 (20), p.5130-5140

2016

Volltextzugriff (PDF)

Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers

Clinical therapeutics, 2004-10, Vol.26 (10), p.1630-1636

2004

Volltextzugriff (PDF)

Diagnostic and Prognostic Role of α-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?

The American journal of gastroenterology, 2006-03, Vol.101 (3), p.524-532

2006

Volltextzugriff (PDF)

148P Method comparison for detection of epidermal growth factor receptor (EGFR) T790M mutation in matched biopsied tumour sections and plasma samples

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S88-S89

2018

Volltextzugriff (PDF)

An Enhanced System for the Detection and Active Cancellation of Snoring Signals

2023 IEEE 33rd International Workshop on Machine Learning for Signal Processing (MLSP), 2023, p.1-6

2023

Volltextzugriff (PDF)

Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study

Digestive and liver disease, 2005-04, Vol.37 (4), p.254-259

2005

Volltextzugriff (PDF)

An investigation of components of variance and tachyphylaxis in a placebo‐controlled intravenous tyramine study

British journal of clinical pharmacology, 2004-05, Vol.57 (5), p.657-660

2004

Volltextzugriff (PDF)

FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S227-S228

2021

Volltextzugriff (PDF)

P1.01-134 SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S415-S416

2019

Volltextzugriff (PDF)

1 – 25 von 325

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(302)
Mit Volltextzugriff
(223)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Some Identities Involving the Cesàro Average of the Goldbach Numbers

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Recent advances in the natural history of hepatocellular carcinoma

Aspartyl‐asparagyl β hydroxylase over‐expression in human hepatoma is linked to activation of insulin‐like growth factor and notch signaling mechanisms

LBA2_PR Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

The effect of fluconazole on the pharmacokinetics of rosuvastatin

134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

Aspartyl-(asparaginyl)-β-hydroxylase regulates hepatocellular carcinoma invasiveness

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers

Diagnostic and Prognostic Role of α-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?

148P Method comparison for detection of epidermal growth factor receptor (EGFR) T790M mutation in matched biopsied tumour sections and plasma samples

An Enhanced System for the Detection and Active Cancellation of Snoring Signals

Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

An investigation of components of variance and tachyphylaxis in a placebo‐controlled intravenous tyramine study

FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

P1.01-134 SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

Suchergebnisse filtern